Marinus Pharmaceuticals Starts Phase 2 Trial

Marinus Pharmaceuticals, a developer of drugs to treat epilepsy and neuropsychiatric disorders, Tuesday said it started a phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of the drug ganaxolone IV in women diagnosed with severe postpartum depression. Marinus said data from the clinical trial would be available in H2 2017.

The company said, “We believe there is a strong mechanistic rationale for ganaxolone to provide a meaningful therapeutic benefit to these mothers struggling with postpartum depression for which there are no approved therapies.”

Leave A Reply

Your email address will not be published.